InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
T+90 hit rate
13%
T+90 mean return
-31.0%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by McClung David, Chief Financial Officer. Officer active across 1 company, notably BioCardia, Inc.. Cumulatively, 15 reports have been logged. Split: 2 buys · 0 sell. Total volume traded: €26k. Activity tracked since 10 June 2021. The latest transaction was disclosed on 2 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
23,125 shares@ US$1.240.16% mcap6.5% of flowCommon StockSEC:0001437749-26-022968:0
60,483 sharesCommon StockSEC:0001437749-26-022364:0
13,123 shares@ US$1.9056.1% of flowCommon StockSEC:0001437749-25-013200:0
Ideal exit: 18 Jan 2026 (T+270)
24,193 shares@ US$2.6516.2% of flowCommon StockSEC:0001437749-24-031410:0
8,333 shares@ US$3.006.2% of flowCommon StockSEC:0001437749-24-028511:0
4,280 shares@ US$2.3362.5% of flowCommon StockSEC:0001437749-23-018552:0
20,676 shares@ US$1.779.4% of flowCommon StockSEC:0001437749-23-016522:0
61,389 shares@ US$1.7026.7% of flowCommon StockSEC:0001437749-23-015516:0
17,347 shares@ US$1.326.1% of flowCommon StockSEC:0001437749-23-009766:0
8,928 shares@ US$1.683.9% of flowCommon StockSEC:0001437749-22-029314:0
2,000 shares@ US$2.071.2% of flowCommon StockSEC:0001437749-22-023876:0
Ideal exit: 7 Jul 2023 (T+270)
20,632 shares@ US$1.320.24% mcap33.5% of flowCommon StockSEC:0001437749-22-012952:0
50,345 shares0Common StockSEC:0001437749-22-009165:0
7,274 shares@ US$4.350.24% mcap33.2% of flowCommon StockSEC:0001437749-21-014633:0
7,274 shares@ US$4.357.2% of flowCommon StockSEC:0001437749-21-014633
15 of 15 declarations
About McClung David
David McClung is the Chief Financial Officer at BioCardia, Inc. He is responsible for the financial management of the company, overseeing financial planning and reporting. His role is crucial in ensuring BioCardia's financial health and growth in the biotechnology sector.
